Ticker > Company >

Bal Pharma share price

Bal Pharma Ltd.

NSE: BALPHARMA BSE: 524824 SECTOR: Pharmaceuticals & Drugs  30.17 K   48   7

97.10
+0.42 (0.43%)
NSE: Today, 12:34 PM

Price Summary

Today's High

₹ 98.11

Today's Low

₹ 97.01

52 Week High

₹ 157.98

52 Week Low

₹ 78.06

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

154.63 Cr.

Enterprise Value

275.33 Cr.

No. of Shares

1.59 Cr.

P/E

19.83

P/B

1.56

Face Value

₹ 10

Div. Yield

1.22 %

Book Value (TTM)

₹  62.06

CASH

13.13 Cr.

DEBT

133.83 Cr.

Promoter Holding

50.86 %

EPS (TTM)

₹  4.9

Sales Growth

11.69%

ROE

10.3 %

ROCE

11.95%

Profit Growth

67.68 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Bal Pharma Ltd.

Diabend PROBETES Aziwin Rigafix Glyin Secremet and Secretag PROLIFE Telong Aclotil

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year11.69%
3 Year10.74%
5 Year8.7%

Profit Growth

1 Year67.68%
3 Year4.13%
5 Year8.73%

ROE%

1 Year10.3%
3 Year9.19%
5 Year5.54%

ROCE %

1 Year11.95%
3 Year11.54%
5 Year9.86%

Debt/Equity

1.2756

Price to Cash Flow

5.34

Interest Cover Ratio

1.7851

CFO/PAT (5 Yr. Avg.)

3.84740308753307

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 50.86 0.00
Mar 2025 50.86 0.00
Dec 2024 50.86 0.00
Sep 2024 50.86 0.00
Jun 2024 51.23 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.29831584828692.
  • The company has an efficient Cash Conversion Cycle of 19.0085 days.
  • The company has a good cash flow management; CFO/PAT stands at 3.84740308753307.
  • The company has a high promoter holding of 50.86%.

 Limitations

  • The company has shown a poor profit growth of 4.13444943146157% for the Past 3 years.
  • The company has shown a poor revenue growth of 10.7363764218565% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 94.58 73.13 74.7 72.89 81.78
Total Expenditure 85.4 66.06 67.22 65.16 73.95
Operating Profit 9.18 7.07 7.48 7.73 7.83
Other Income 1.86 0.82 0.35 0.82 0.99
Interest 3.34 3.71 4.18 5.01 3.94
Depreciation 2.14 2.08 2.12 2.33 2.07
Exceptional Items 0 0 0 0 0
Profit Before Tax 5.55 2.11 1.52 1.2 2.82
Tax 0.21 0.36 0.32 0.05 -2.79
Profit After Tax 5.34 1.75 1.2 1.16 5.61
Adjusted EPS (Rs) 3.38 1.11 0.76 0.73 3.52

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 170.67 249.31 280.37 303.1 338.54
Total Expenditure 163.66 222.81 256.93 276.67 305.92
Operating Profit 7.02 26.5 23.44 26.43 32.62
Other Income 3.63 2.69 6.46 2.19 3.35
Interest 12.69 12.14 10.6 12.59 15.42
Depreciation 7.03 7.26 7.24 7.48 8.45
Exceptional Items 0 0 0 0 0
Profit Before Tax -9.08 9.8 12.06 8.55 12.11
Tax -0.17 0.7 3.48 2.42 1.83
Net Profit -8.9 9.1 8.58 6.13 10.27
Adjusted EPS (Rs.) -6.28 6.14 5.79 3.9 6.5

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 14.17 14.82 14.82 15.69 15.8
Total Reserves 51.77 64.5 72.5 80.34 89.78
Borrowings 23.15 23.93 27.01 30.52 36.35
Other N/C liabilities 10.27 11.42 9.32 8.99 10.21
Current liabilities 139.95 146.87 166.1 212.15 209.16
Total Liabilities 239.31 261.54 289.76 347.7 361.3
Assets
Net Block 56.14 52.65 52.9 63.07 64.56
Capital WIP 0.11 0 1.16 0 0.47
Intangible WIP 0 0 0 0 0
Investments 7.42 8.4 8.4 8.4 9.58
Loans & Advances 5.38 4.8 6.29 4.51 5.1
Other N/C Assets 1.56 2.49 2.82 1.78 0.45
Current Assets 168.71 193.2 218.2 269.95 281.14
Total Assets 239.31 261.54 289.76 347.7 361.3
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -9.08 9.8 12.06 8.55 12.11
Adjustment 16.69 17.43 13.99 18.85 19.66
Changes in Assets & Liabilities 14.27 -16.89 5.64 -21.52 1.73
Tax Paid -0.17 -0.11 -1.12 -0.5 -4.54
Operating Cash Flow 21.71 10.23 30.57 5.38 28.95
Investing Cash Flow -3.3 -6.66 -13.43 -22.08 -18.43
Financing Cash Flow -19.94 -3.36 -17.22 17.12 -7.71
Net Cash Flow -1.52 0.21 -0.08 0.42 2.81

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 51.23 50.86 50.86 50.86 50.86
anand surana 3.33 3.30 3.30 3.30 3.30
anita chandraprakash siro... 0.78 0.77 0.77 0.77 0.77
anita siroya 6.64 6.59 6.59 6.59 6.59
archana surana 1.80 1.79 1.79 1.79 1.79
chandraprakash dheerajmal... 3.08 3.06 3.06 3.06 3.06
dilip surana (huf) - - - - 1.07
dilip surana 3.01 2.98 2.98 2.98 2.98
jivi dheerajmal siroya 0.29 0.29 0.29 0.29 0.29
micro labs limited 12.73 12.64 12.64 12.64 12.64
monica surana 1.14 1.13 1.13 1.13 1.13
shailesh siroya 17.37 17.24 17.24 17.24 17.24
dilip surana (huf) 1.08 1.07 1.07 1.07 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 48.77 49.14 49.14 49.14 49.14
asha tapidas dodhia - - - - 1.84
gautam chand mehta 1.29 1.19 1.19 1.19 1.19
investor education and pr... - - 0.78 0.83 0.83
llp 0.21 0.16 0.06 0.11 0.09
naresh d p - 1.88 1.88 - 1.88
prakash chandra jain 3.68 3.65 3.65 3.65 3.65
ram keshav murthy 3.65 3.31 3.31 3.31 3.31
shreya mardia 1.90 1.88 1.88 1.88 1.88
asha tapidas dhodia 1.86 1.84 1.84 1.84 -
naresh d.p 1.90 - - 1.88 -
investor education and pr... 0.79 0.78 - - -

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit ICRA
Credit ICRA
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q1FY23
Presentation Q1FY23

Company News

 No Latest News available for this company.Report us

Bal Pharma Stock Price Analysis and Quick Research Report. Is Bal Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Bal Pharma and its performance over the period of time. Bal Pharma stock price today is Rs 97.1.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Bal Pharma cash from the operating activity was Rs 28.9522 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Bal Pharma has a Debt to Equity ratio of 1.2756 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Bal Pharma , the EPS growth was 66.4626 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Bal Pharma has OPM of 9.63664844232541 % which is a bad sign for profitability.
     
  • ROE: Bal Pharma have a average ROE of 10.2952 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Bal Pharma is Rs 97.1. One can use valuation calculators of ticker to know if Bal Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Bal Pharma
X